Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma

During last few years, the approaches to the management of patients with severe asthma have been revised. Monoclonal antibodies (MABs), inhibitors of interleukin-5 (reslizumab, mepolizumab, benralizumab) have been recently introduced for the treatment of severe eosinophilic asthma. The mentioned dru...

Full description

Bibliographic Details
Main Authors: S. K. Zyryanov, S. N. Avdeev, D. A. Ivanov, M. V. Zhuravleva, N. P. Kniajeskaia, N. V. Matveev, N. A. Nenasheva, D. S. Fomina, M. Iu. Frolov
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2020-12-01
Series:Терапевтический архив
Subjects:
pharmacoeconomic study
reslizumab
mepolizumab
benralizumab
severe asthma
eosinophilic asthma
disease-related groups
regions of russia
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/60292/43467

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/60292/43467

Similar Items